Foghorn Therapeutics
FHTX
102 hedge funds and large institutions have $219M invested in Foghorn Therapeutics in 2026 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 26 reducing their positions, and 14 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 26
48% more capital inflows, than outflows
Capital inflows: $6.48M | Capital outflows: $4.39M
0.8% more ownership
Funds ownership: 75.71% → 76.51% (+0.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
3% less funds holding
Funds holding: 105 → 102 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.16M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$541K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$487K |
| 4 |
BGI
B Group Inc
Dallas,
Texas
|
+$435K |
| 5 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
+$407K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.51M |
| 2 |
Sio Capital Management
New York
|
-$587K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
-$499K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$287K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$183K |
FHTX Hedge Fund Activity: Q2 2026 in Review
102 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q2 2026, worth a combined $219M — up 3.2% from $212M a quarter earlier.
Fund positioning in FHTX was balanced in Q2 2026: 14 funds opened new positions, 14 closed out, 40 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $1.16M. The largest seller was Fidelity Investments, cutting an estimated $1.51M.
- 102 institutional investors held Foghorn Therapeutics (FHTX) as of Q2 2026, down from 105 in Q1 2026.
- Funds reported $219M of Foghorn Therapeutics stock for Q2 2026, up 3.2% quarter-over-quarter.
- 14 funds opened new Foghorn Therapeutics positions in Q2 2026 and 14 closed out, a net change of 0 holders.
- The largest Foghorn Therapeutics buyer in Q2 2026 was BlackRock, an estimated $1.16M added.
- The largest Foghorn Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $1.51M sold.
Based on aggregated 13F filings for Q2 2026.